GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 23, 2013, Pages 9529-9534

  Meyer, Rebecca C ^a   Giddens, Michelle M ^a   Schaefer, Stacy A ^a   Hall, Randy A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Deorphanization; Gpcr; Mapk; Neurodegeneration; Peptide

Indexed keywords

CYCLIC AMP; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; GPR37 PROTEIN; GPR37L1 PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MITOGEN ACTIVATED PROTEIN KINASE; PERTUSSIS TOXIN; PROSAPOSIN; PROSAPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; ENDOCYTOSIS; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

DEORPHANIZATION; GPCR; MAPK; NEURODEGENERATION; PEPTIDE;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; GENE KNOCKDOWN TECHNIQUES; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTORS; OXIDATIVE STRESS; PHOSPHORYLATION; POLYSORBATES; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; SAPOSINS; SULFUR RADIOISOTOPES;

EID: 84878715626     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219004110     Document Type: Article

References (76)

1. Lagerström MC, Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7(4):339-357.
2. Civelli O, Saito Y, Wang Z, Nothacker HP, Reinscheid RK (2006) Orphan GPCRs and their ligands. Pharmacol Ther 110(3):525-532.
3. Marazziti D, et al. (1997) Cloning of GPR37, a gene located on chromosome 7 encoding a putative G-protein-coupled peptide receptor, from a human frontal brain EST library. Genomics 45(1):68-77.
4. Zeng Z, Su K, Kyaw H, Li Y (1997) A novel endothelin receptor type-B-like gene enriched in the brain. Biochem Biophys Res Commun 233(2):559-567.
5. Donohue PJ, et al. (1998) A human gene encodes a putative G protein-coupled receptor highly expressed in the central nervous system. Brain ResMol Brain Res 54(1):152-160.
6. Marazziti D, Gallo A, Golini E, Matteoni R, Tocchini-Valentini GP (1998) Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. Genomics 53(3): 315-324.
7. Valdenaire O, et al. (1998) A new family of orphan G protein-coupled receptors predominantly expressed in the brain. FEBS Lett 424(3):193-196.
8. Leng N, Gu G, Simerly RB, Spindel ER (1999) Molecular cloning and characterization of two putative G protein-coupled receptors which are highly expressed in the central nervous system. Brain Res Mol Brain Res 69(1):73-83.
9. Imai Y, et al. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105(7):891-902.
10. Cahoy JD, et al. (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28(1):264-278.
11. Walden H, Martinez-Torres RJ (2012) Regulation of Parkin E3 ubiquitin ligase activity. Cell Mol Life Sci 69(18):3053-3067.
12. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37(6): 911-924.
13. Obeso JA, et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16(6): 653-661.
14. Marazziti D, et al. (2004) Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc Natl Acad Sci USA 101(27):10189-10194.
15. Imai Y, et al. (2007) Pael receptor is involved in dopamine metabolism in the nigrostriatal system. Neurosci Res 59(4):413-425.
16. Marazziti D, et al. (2007) GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc Natl Acad Sci USA 104(23):9846-9851.
17. Rezgaoui M, et al. (2006) The neuropeptide head activator is a high-affinity ligand for the orphan G-protein-coupled receptor GPR37. J Cell Sci 119(Pt 3):542-549.
18. Gandía J, et al. (2013) The Parkinson's disease-associated GPR37 receptor-mediated cytotoxicity is controlled by its intracellular cysteine-rich domain. J Neurochem 125(3):362-372.
19. Bodenmüller H, Schaller HC, Darai G (1980) Human hypothalamus and intestine contain a hydra-neuropeptide. Neurosci Lett 16(1):71-74.
20. Bodenmüller H, Schaller HC (1981) Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans. Nature 293(5833):579-580.
21. O'Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y (1994) Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci USA 91(20):9593-9596.
22. Sano A, et al. (1994) Protection by prosaposin against ischemia-induced learning disability and neuronal loss. Biochem Biophys Res Commun 204(2):994-1000.
23. O'Brien JS, et al. (1995) Identification of the neurotrophic factor sequence of prosaposin. FASEB J 9(8):681-685.
24. Kotani Y, et al. (1996) A hydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo. J Neurochem 66(5): 2197-2200.
25. Hiraiwa M, Campana WM, Martin BM, O'Brien JS (1997) Prosaposin receptor: Evidence for a G-protein-associated receptor. Biochem Biophys Res Commun 240(2): 415-418.
26. Hiraiwa M, Taylor EM, Campana WM, Darin SJ, O'Brien JS (1997) Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc Natl Acad Sci USA 94(9):4778-4781.
27. Campana WM, et al. (1998) Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 19(2):237-244.
28. Campana WM, Hiraiwa M, O'Brien JS (1998) Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 12(3):307-314.
29. Misasi R, et al. (1998) Colocalization and complex formation between prosaposin and monosialoganglioside GM3 in neural cells. J Neurochem 71(6):2313-2321.
30. Tsuboi K, Hiraiwa M, O'Brien JS (1998) Prosaposin prevents programmed cell death of rat cerebellar granule neurons in culture. Brain Res Dev Brain Res 110(2):249-255.
31. Campana WM, Darin SJ, O'Brien JS (1999) Phosphatidylinositol 3-kinase and Akt protein kinase mediate IGF-I- and prosaptide-induced survival in Schwann cells. J Neurosci Res 57(3):332-341.
32. Igase K, et al. (1999) An 18-mer peptide fragment of prosaposin ameliorates place navigation disability, cortical infarction, and retrograde thalamic degeneration in rats with focal cerebral ischemia. J Cereb Blood Flow Metab 19(3):298-306.
33. Campana WM, Mohiuddin L, Misasi R, O'Brien JS, Calcutt NA (2000) Prosaposin-derived peptides enhanced sprouting of sensory neurons in vitro and induced sprouting at motor endplates in vivo. J Peripher Nerv Syst 5(3):126-130.
34. Lu AG, Otero DA, HiraiwaM, O'Brien JS (2000) Neuroprotective effect of retro-inverso Prosaptide D5 on focal cerebral ischemia in rat. Neuroreport 11(8):1791-1794.
35. Taylor EM, Otero DA, Banks WA, O'Brien JS (2000) Retro-inverso prosaptide peptides retain bioactivity, are stable In vivo, and are blood-brain barrier permeable. J Pharmacol Exp Ther 295(1):190-194.
36. Taylor EM, Otero DA, Banks WA, O'Brien JS (2000) Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration. J Pharmacol Exp Ther 293(2):403-409.
37. Yan L, Otero DA, Hiraiwa M, O'Brien JS (2000) Prosaptide D5 reverses hyperalgesia: inhibition of calcium channels through a pertussis toxin-sensitive G-protein mechanism in the rat. Neurosci Lett 278(1-2):120-122.
38. Liu J, Wang CY, O'Brien JS (2001) Prosaptide D5, a retro-inverso 11-mer peptidomimetic, rescued dopaminergic neurons in a model of Parkinson's disease. FASEB J 15(6): 1080-1082.
39. Morita F, et al. (2001) Protective effect of a prosaposin-derived, 18-mer peptide on slowly progressive neuronal degeneration after brief ischemia. J Cereb Blood Flow Metab 21(11):1295-1302.
40. Jolivalt CG, Vu Y, Mizisin LM, Mizisin AP, Calcutt NA (2008) Impaired prosaposin secretion during nerve regeneration in diabetic rats and protection of nerve regeneration by a prosaposin-derived peptide. J Neuropathol Exp Neurol 67(7): 702-710.
41. Ochiai T, et al. (2008) Molecular mechanism for neuro-protective effect of prosaposin against oxidative stress: Its regulation of dimeric transcription factor formation. Biochim Biophys Acta 1780(12):1441-1447.
42. Li N, Sarojini H, An J, Wang E (2010) Prosaposin in the secretome of marrow stromaderived neural progenitor cells protects neural cells from apoptotic death. J Neurochem 112(6):1527-1538.
43. Lee TJ, Sartor O, Luftig RB, Koochekpour S (2004) Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer 3:31.
44. Dunham JH, Meyer RC, Garcia EL, Hall RA (2009) GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions. Biochemistry 48(43):10286-10297.
45. von Zastrow M (2001) Role of endocytosis in signalling and regulation of G-proteincoupled receptors. Biochem Soc Trans 29(Pt 4):500-504.
46. Gasser MC, Berti I, Hauser KF, Fischer-Colbrie R, Saria A (2003) Secretoneurin promotes pertussis toxin-sensitive neurite outgrowth in cerebellar granule cells. J Neurochem 85(3):662-669.
47. Igwe OJ, Kim DC, Seybold VS, Larson AA (1990) Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes. J Neurosci 10(11):3653-3663.
48. Lakatos A, Prinster S, Vicentic A, Hall RA, Kuhar MJ (2005) Cocaine- and amphetamine- regulated transcript (CART) peptide activates the extracellular signal-regulated kinase (ERK) pathway in AtT20 cells via putative G-protein coupled receptors. Neurosci Lett 384(1-2):198-202.
49. Lin Y, Hall RA, Kuhar MJ (2011) CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: Identification of PACAP 6-38 as a CART receptor antagonist. Neuropeptides 45(5):351-358.
50. Chiu S, Wong YW, Wan YP, Chiu P, Mishra RK (1983) Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms? Prog Neuropsychopharmacol Biol Psychiatry 7(4-6):739-742.
51. Akiyama N, et al. (1992) Biotin derivatives of endothelin: Utilization for affinity purification of endothelin receptor. Protein Expr Purif 3(5):427-433.
52. Saravanan K, Paramasivam M, Dey S, Singh TP, Srinivasan A (2004) Biotinyl endothelin-1 binding to endothelin receptor and its applications. J Cardiovasc Pharmacol 44(3):287-293.
53. Campana WM, Hiraiwa M, Addison KC, O'Brien JS (1996) Induction of MAPK phosphorylation by prosaposin and prosaptide in PC12 cells. Biochem Biophys Res Commun 229(3):706-712.
54. Hiraiwa M, Campana WM, Wang CY, Otero DA, O'Brien JS (2001) A retro-inverso Prosaptide D5 promotes a myelination process in developing rats. Brain Res Dev Brain Res 128(1):73-76.
55. Misasi R, et al. (2001) Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: Activation of ERKs and sphingosine kinase. FASEB J 15(2):467-474.
56. Galey D, et al. (2003) Differential transcriptional regulation by human immunodeficiency virus type 1 and gp120 in human astrocytes. J Neurovirol 9(3):358-371.
57. Calcutt NA, et al. (1999) Prosaposin gene expression and the efficacy of a prosaposinderived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats. J Neuropathol Exp Neurol 58(6):628-636.
58. Xu C, et al. (2012) The interaction of the second Kunitz-type domain (KD2) of TFPI-2 with a novel interaction partner, prosaposin, mediates the inhibition of the invasion and migration of human fibrosarcoma cells. Biochem J 441(2):665-674.
59. Hiraiwa M, Campana WM, Mizisin AP, Mohiuddin L, O'Brien JS (1999) Prosaposin: A myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 26(4):353-360.
60. Cove J, Morales CR, Baranes D (2006) SGP-1 increases dendritic and synaptic development dependent on synaptic activity. Neurosci Res 56(4):372-385.
61. Misasi R, et al. (2009) Biochemistry and neurobiology of prosaposin: A potential therapeutic neuro-effector. Cent Nerv Syst Agents Med Chem 9(2):119-131.
62. Kishimoto Y, Hiraiwa M, O'Brien JS (1992) Saposins: Structure, function, distribution, and molecular genetics. J Lipid Res 33(9):1255-1267.
63. Hineno T, et al. (1991) Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun 176(2):668-674.
64. Fujita N, et al. (1996) Targeted disruption of the mouse sphingolipid activator protein gene: A complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 5(6):711-725.
65. Oya Y, Nakayasu H, Fujita N, Suzuki K, Suzuki K (1998) Pathological study of mice with total deficiency of sphingolipid activator proteins (SAP knockout mice). Acta Neuropathol 96(1):29-40.
66. Sun Y, et al. (2007) Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking. Hum Mol Genet 16(8):957-971.
67. Sun Y, et al. (2010) Specific saposin C deficiency: CNS impairment and acid betaglucosidase effects in the mouse. Hum Mol Genet 19(4):634-647.
68. Yoneshige A, Suzuki K, Suzuki K, Matsuda J (2010) A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice. J Neurosci Res 88(10):2118-2134.
69. Elleder M, et al. (2005) Prosaposin deficiency - A rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. Neuropediatrics 36(3):171-180.
70. Sikora J, Harzer K, Elleder M (2007) Neurolysosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin. Acta Neuropathol 113(2):163-175.
71. Kitao Y, et al. (2007) Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 16(1):50-60.
72. Wang HQ, et al. (2008) Pael-R transgenic mice crossed with parkin deficient mice displayed progressive and selective catecholaminergic neuronal loss. J Neurochem 107(1):171-185.
73. Dusonchet J, Bensadoun JC, Schneider BL, Aebischer P (2009) Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol Dis 35(1):32-41.
74. Marazziti D, et al. (2009) Induction of macroautophagy by overexpression of the Parkinson's disease-associated GPR37 receptor. FASEB J 23(6):1978-1987.
75. Lundius EG, Stroth N, Vukojevic V, Terenius L, Svenningsson P (2013) Functional GPR37 trafficking protects against toxicity induced by 6-OHDA, MPP+ or rotenone in a catecholaminergic cell line. J Neurochem 124(3):410-417.
76. Chen J, et al. (2008) Expression patterns in alternative splicing forms of prosaposin mRNA in the rat facial nerve nucleus after facial nerve transection. Neurosci Res 60(1): 82-94.